Aptamer:toxin conjugates that specifically target prostate tumor cells.

We have used RNA aptamer:gelonin conjugates to target and specifically destroy cells overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA). Aptamer:toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These results validate the notion that "escort aptamers" may be useful for the treatment of specific tumors expressing unique antigen targets.

[1]  A. Rajasekaran,et al.  Is prostate-specific membrane antigen a multifunctional protein? , 2005, American journal of physiology. Cell physiology.

[2]  John I. Loewenstein,et al.  Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. , 2003, Ophthalmology.

[3]  Johannes Waltenberger,et al.  In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  B. Hicke,et al.  Escort aptamers: a delivery service for diagnosis and therapy. , 2000, The Journal of clinical investigation.

[5]  Laura A Lavery,et al.  Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. , 2006, Biosensors & bioelectronics.

[6]  H. Schluesener,et al.  Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels , 2001, The Journal of Biological Chemistry.

[7]  M. Rosenblum,et al.  Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. , 2003, Cancer research.

[8]  L. Gold,et al.  High affinity ligands from in vitro selection: complex targets. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[10]  A. Kung,et al.  Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties. , 1994, The Journal of biological chemistry.

[11]  M. Famulok,et al.  Oligonucleotide aptamers that recognize small molecules. , 1999, Current opinion in structural biology.

[12]  M. Rosenblum,et al.  Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin , 1999, Cancer Chemotherapy and Pharmacology.

[13]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[14]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[15]  Bertrand Tavitian,et al.  Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase , 2005, PLoS biology.

[16]  L. Gold,et al.  A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  B. Sullenger,et al.  RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.

[18]  Amy C Yan,et al.  Aptamers: prospects in therapeutics and biomedicine. , 2005, Frontiers in bioscience : a journal and virtual library.

[19]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.